- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01317121
Multi-site Communication Deficits in Schizophrenia
February 9, 2021 updated by: CMulert, Universitätsklinikum Hamburg-Eppendorf
Multi-site Communication Deficits Underlying Cognitive Dysfunction in the Prodromal Phase and First Episode of Schizophrenia
Multi-site Communication Deficits Underlying Cognitive Dysfunction in the Prodromal Phase and First Episode of Schizophrenia
Study Overview
Status
Completed
Conditions
Detailed Description
Abnormal long-range connectivity between brain areas and corresponding impaired synchronization of oscillatory rhythms in neuronal networks represent an important pathophysiological mechanism underlying schizophrenia.
Although schizophrenia is considered as a neurodevelopmental disorder the mechanisms by which the abnormal neural circuitry and communication develops before the onset of clinical symptoms are unknown.
This project aims to investigate the relationship between disturbed neural synchronization and cognitive deficits in the prodromal phase of schizophrenia and is intended to identify patients with increased risk for developing schizophrenia.
Present approaches to describe subjects at risk for psychosis based on clinical features have not been completely convincing since psychiatric symptoms in the prodromal phase are often too unspecific.
Recent studies suggest that detecting cognitive deficits might help for a more precise identification of high risk subjects.
However, the underlying neurophysiological mechanisms have not yet been investigated sufficiently.
Precise identification of subjects with high risk for switching to schizophrenia would be very important since interventional strategies such as medical treatment even with second generation antipsychotics are not completely free of risk and therefore should be limited to subjects with a maximal benefit.
In this project subjects at risk for psychosis will be investigated with electroencephalography (EEG), magnetoencephalography (MEG) and simultaneous electroencephalography-functional magnetic resonance imaging (EEG-fMRI).
Follow up investigations will be performed after switching to schizophrenia has occurred or not.
Neural synchronization between the prefrontal cortex and the hippocampal formation will be investigated using a working memory paradigm.
Here, different levels of memory load will be investigated using the n-back paradigm.
Earlier studies showed disturbed functional and effective connectivity between the hippocampus and the prefrontal cortex both in patients with schizophrenia and subjects at risk.
Neural synchronization between the prefrontal cortex and sensory areas will be investigated with different attentional paradigms.
Here, tones will be presented that have to be responded to by button press.
Earlier studies demonstrated disturbed auditory evoked gamma oscillations in patients with schizophrenia and unaffected siblings.
Neural oscillations will be recorded with 64-channel EEG and localized by means of simultaneous functional magnetic resonance imaging (fMRI).
Integration of EEG and fMRI will be performed using single-trial coupling in order to detect brain regions involved in specific oscillatory rhythms.
Using both paradigms, neural long-range synchronization will be analyzed.
In addition, dynamic causal modelling will be used for further characterization of functional relationships among brain regions involved.
The investigators expect a functional relationship between cognitive deficits in subjects with prodromal schizophrenia and subjects with a first episode of schizophrenia with regards to long range neural synchronization.
In addition, the investigators expect to identify subjects at high risk for schizophrenia with the analysis of disturbed long range synchronization.
Study Type
Observational
Enrollment (Actual)
90
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamburg, Germany, 20246
- Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf (UKE)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Three groups of subjects will be included: patients with a first episode of schizophrenia, subjects at increased risk for schizophrenia, and healthy control subjects.
Description
Inclusion criteria schizophrenic patients:
- Signed written informed consent.
- Inpatients of the Clinic for Psychiatry and Psychotherapy of the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany.
- Diagnosis of schizophrenia according to ICD-10 and DSM-IV criteria.
Exclusion criteria schizophrenic patients:
- Epilepsy or other disorders of the nervous system, further psychiatric or neurological disorders.
- Suicidal tendencies.
- Acute or lifetime alcohol abuse.
- Hearing impairment.
- Intelligence quotient (IQ) below average.
- Non-magnetoencephalography(MEG)/ magnetic resonance imaging(MRI) compatible metallic implants.
Inclusion criteria subjects at risk:
- Signed written informed consent.
- Outpatients of the early diagnosis center of the University Department of Psychiatry at the University Hospital Hamburg-Eppendorf (UKE)Germany.
- Meeting high risk criteria for schizophrenia according to the Structured Interview for Prodromal Syndromes (SIPS).
Exclusion criteria subjects at risk:
- Epilepsy or other disorders of the nervous system, further psychiatric or neurological disorders.
- Suicidal tendencies.
- Acute or lifetime alcohol abuse.
- Hearing impairment.
- IQ below average.
- Non-MEG/MRI compatible metallic implants.
Inclusion criteria healthy controls:
- Signed written informed consent.
- Healthy male and female subjects recruited from students and hospital staff of the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany.
Exclusion criteria healthy controls:
- Acute or lifetime psychiatric disorder.
- Suicidal tendencies.
- Epilepsy or other disorders of the nervous system.
- First degree relative with a psychiatric disorder.
- Intake of medication affecting the central nervous system.
- Acute or lifetime alcohol abuse.
- Hearing impairment.
- IQ below average.
- Non-MEG/MRI compatible metallic implants.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Subjects at risk for psychosis
Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany.
Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
|
|
Patients with a first episode of schizophrenia
Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany.
All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
|
|
Healthy control subjects
Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany.
They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Brain function
Time Frame: baseline and one-year follow-up
|
baseline and one-year follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Christoph Mulert, Prof. Dr., University Medical Center Hamburg-Eppendorf, Department of Psychiatry
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2011
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
March 15, 2011
First Submitted That Met QC Criteria
March 15, 2011
First Posted (Estimate)
March 17, 2011
Study Record Updates
Last Update Posted (Actual)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 9, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NeuroSFB-PV3632
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.